贵州医科大学优秀青年拔尖人才项目，2023.7-2028.6，100万元，在研，主持。
教学情况
主讲本科药理学课程。
论文、专著及专利等
在学术刊物上发表科研论文30余篇。代表作：
第一作者
1. Hongjin Chen, et al. Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer, Genomics. 2020 Nov 6;S0888-7543(20)32003-6. doi: 10.1016/j.ygeno.2020.10.039.
2. Hongjin Chen, et al. Inhibition of myeloid differentiation factor 2 by baicalein protects against acute lung injury. Phytomedicine, 2019, 63:152997.
3. Hong-Jin Chen, et al. Understanding the inflammation-cancer transformation in the development of primary liver cancer, Hepatoma Research, 2018;4:29. DOI: 10.20517/2394-5079.2018.18.
4. Hongjin Chen, et al. Inhibition of high glucose-induced inflammation and fibrosis by a novel curcumin derivative prevents renal and heart injury in diabetic mice. Toxicology Letters, 2017, 278:48-58.
5：Hongjin Chen, et al. Overexpression of RhoV promotes the progression and EGFR-TKI resistance of lung adenocarcinoma, Frontiers in Oncology, 2021 Mar 9:11:619013.
6：Hongjin Chen, et al. Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways, Cancer Gene Therapy, 2022 Jul;29(7):1033-1042.
7：Hongjin Chen, et al. Curcumin Derivative C66 Suppresses Pancreatic Cancer Progression through the Inhibition of JNK-Mediated Inflammation, Molecules, 2022 May 11;27(10):3076.
8：Hongjin Chen, et al. Acute or chronic inflammation role in gastrointestinal oncology, World J Gastrointest Oncol. 2022 Aug 15;14(8):1600-1603.
9：Hongjin Chen, et al. Multifunctional roles of inflammation and its causative factors in primary liver cancer: A literature review. World J Hepatol .2023 Dec 27;15(12):1258-1271.
10: Hongjin Chen, et al. Effects of vitamin family members on insulin resistance and diabetes complications. World J Diabetes. 2024 Mar 15;15(3):568-571.
通讯作者
1. Yi Zhang# , Hui Liu# , Wenjing Jia# , Jiayu Qi, Wentao Zhang, Wenxin Zhang, Guang Liang, Yali Zhang, Hongjin Chen*. Myeloid differentiation protein 2 mediates angiotensin II induced liver inflammation and fibrosis in mice. Molecules, 2020, 25(1), 25.
2. Jue Bai#, Si-Yuan Yang#, Shao-Mei Yu, Ying Cao, Xuan-Yi Hu, Xiong Chen, Ying-Nan Song*, Hong-Jin Chen*, IGFBP5 mediates the therapeutic effect of isoliquiritigenin in myocardial ischemia-reperfusion injury via AKT/GLUT4 regulated insulin resistance, Frontier in Pharmacology,2025 Apr 29:16:1544869.
3.miR-92a-1-5p targeting MEF2A induced Insulin Resistance in Myocardial Ischemia/Reperfusion Injury，Biochem Biophys Res Commun，2025 Jul 1:768:151938.
4. Isoliquiritigenin inhibited complete Freund's adjuvant-induced chronic inflammatory pain via the CCL7/CCR2/ERK pathway in dorsal root ganglia neurons of mice，International Immunopharmacology，Volume 170, 1 February 2026, 116059
并列第一作者（6篇）
1. Xiaozhong Huang, et al, Cell Death Dis. 2020 Dec 7;11(12):1040. doi: 10.1038/s41419-020-03260-9.（SCI,二区，IF=6.3，共一/自然序列：第三作者）
2. Yali Zhang, et al, BBA - Molecular Basis of Disease, 2020 Jan 14;1866(5):165683.（SCI,二区，IF=4.8，共一/自然序列：第二作者）
3. Chunyong Ding, et al, Chemical Science, 2019, 10:4667-4672.（SCI,一区，IF=9.34，共一/自然序列：第二作者）
4. Lingfeng Chen, et al. European Journal of Medicinal Chemistry, 2019: 161, 22-38.（SCI,一区，IF=5.573，共一/自然序列：第二作者）5. Dandan Liang, et al. BBA - Molecular Basis of Disease, 2018, 1864(1): 133-142.（SCI,二区，IF=4.8，共一/自然序列：第二作者）6. Lingfeng Chen, et al. Eur. J Med. Chem, 2017, 143: 361-375.（SCI,一区，IF=5.573，共一/自然序列：第三作者）
